Alvotech and Dr Reddy's partner to commercialise AVT03 [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
AVT03 is a biosimilar candidate to the reference products Prolia and Xgeva (denosumab). Prolia and Xgeva are used to treat conditions including osteoporosis in postmenopausal women and to prevent skeletal-related events in adults with advanced cancers. The agreement will leverage Dr Reddy's global commercial reach and Alvotech's biosimilar development expertise. Alvotech will be tasked with the development and manufacturing of AVT03. Dr Reddy's Laboratories will handle the registration and commercialisation of the product in the designated markets. The strategic collaboration comes with an undisclosed upfront payment to Alvotech, followed by regulatory and commercial milestone payments, as well as payments based on product sales. The commercialisation rights granted to Dr Reddy's are solely for the US market and semi-exclusive for the UK and European markets. AVT03 is currently an investigational product and not approved by any regulatory agency. In January 2024 Alvot
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Active Pharmaceutical Ingredients (APIs) Market Size Expected to Reach USD 344.91 Billion by 2032 [Yahoo! Finance]Yahoo! Finance
- Global Lenalidomide Drug Market Size To Worth USD 21.47 Billion By 2033 | CAGR Of 5.69% [Yahoo! Finance]Yahoo! Finance
- Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 [Yahoo! Finance]Yahoo! Finance
- Aurigene Pharmaceutical opens biologics facility in Hyderabad, India [Yahoo! Finance]Yahoo! Finance
- Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 5/8/24 - Beat
RDY
Sec Filings
- 6/24/24 - Form 6-K
- 6/21/24 - Form 6-K
- 6/20/24 - Form 6-K
- RDY's page on the SEC website